Open Orphan PLC Directors Change (2449G)
November 24 2020 - 1:00AM
UK Regulatory
TIDMORPH
RNS Number : 2449G
Open Orphan PLC
24 November 2020
24 November 2020
Open Orphan plc
("Open Orphan" or the "Company")
Directors Change
Open Orphan plc (ORPH), a rapidly growing specialist CRO
pharmaceutical services company which is the world leader in the
testing of vaccines and antivirals using human challenge clinical
trials is pleased to announce the appointment of Elaine Sullivan as
a Non-Executive Director to the Board of Open Orphan.
Elaine is a business leader and senior scientist with
international experience in the pharmaceutical industry and Biotech
and is the CEO of Curadh Pharmaceuticals. Elaine has an in-depth
background and knowledge of virology having received a PhD from the
University of Edinburgh in Molecular Virology. She has been a
member of the most senior R&D management teams in Lilly and
AstraZeneca. Elaine also has extensive start-up experience having
been a founder of Carrick Therapeutics and helped to raise over
EUR100m of investor funds as CEO of Carrick in recent years. Elaine
is a Non-Executive Director at IP Group plc and Active Biotech AB
and is a member of the Supervisory Board at Evotec which is listed
on the Frankfurt Stock Exchange.
The Company also announces that Mark Warne, Non-Executive
Director, will be stepping down from the Board of Open Orphan on
the 31(st) of December. Mark had been on the Board of hVIVO plc
prior to its acquisition by Open Orphan and assisted with the
integration of hVIVO with the Open Orphan group.
Cathal Friel, Executive Chairman, Open Orphan, said:
"We are delighted to announce the appointment of Elaine to the
Open Orphan board. Her level of expertise in virology alongside her
exceptional career in the industry will be an excellent addition to
the Company. We look forward to working closely with Elaine who
brings with her a wealth of knowledge and experience and will be
invaluable addition to the Company as we now grow Open Orphan
substantially in its next phase of rapid development."
"We would like to thank Mark Warne for his service to the
Company and for remaining on the Board to allow for a smooth
integration of the companies during the transition period following
the acquisition of hVIVO."
Elaine Sullivan, Incoming Non-Executive Director, Open Orphan,
said:
"I am delighted to join the board of Open Orphan. I have been
impressed by the outstanding
progress that Cathal Friel, the Board and the team have made in
such a short time. I look forward to working with them in the next
stage of the evolution of Open Orphan."
For further information please contact
Open Orphan plc +353 (0)1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser and +44 (0)20 7614
Joint Broker) 5900
John Llewellyn-Lloyd / Benjamin Cryer /
Dan Gee-Summons
+44 (0) 20 7220
finnCap plc (Joint Broker) 500
Geoff Nash / James Thompson/ Richard Chambers
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0)1 679 6363
Anthony Farrell
+44 (0)20 3757
Camarco (Financial PR) 4980
Tom Huddart / Hugo Liddy
Full Name: Elaine Sullivan (née McGlynn)
Age: 59
Current directorships / partnerships Directorships / partnerships
within the last five years
Active Biotech AB Carrick Therapeutics UK Limited
Curadh Pharmaceuticals Limited
Evotec AG
IP Group plc
Dargle Therapeutics Limited
Elaine Sullivan does not hold any shares or options over shares
in the Company.
There is no further information to be disclosed in relation to
Elaine Sullivan's appointment pursuant to AIM Rule 17, paragraph
(g) of Schedule Two of the AIM Rules for Companies or Rule 5.22
(b), Schedule 2 paragraph (g) of Chapter 5: Additional Rules for
the Euronext Growth Market operated by Euronext Dublin.
Notes to Editors - Open Orphan:
Open Orphan is a rapidly growing niche CRO pharmaceutical
services company which is the world leader in the testing of
vaccines and antivirals through the use of human challenge clinical
trials. Conducted from Europe's only 24-bedroom quarantine clinic
with onsite virology providing individually isolated rooms and
connected to our specialist laboratory facility. hVIVO's challenge
studies require healthy volunteers to take part, volunteers are
recruited through FluCamp, learn more at www.FluCamp.com . The
hVIVO facility offers highly specialised virology and immunology
laboratory services to support pre-clinical and clinical
respiratory drug, antiviral, and vaccine discovery and development.
Reliable laboratory analysis underpinned by scientific expertise is
essential when processing and analysing clinical samples. Robust
quality processes support our team of scientists in the delivery of
submission ready data.
The Company has a leading portfolio of 8 viral challenge study
models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD
viral challenge models. As announced in early March, Open Orphan is
rapidly advancing a number of Coronavirus challenge study models
and expects to be helping many COVID-19 vaccine development
companies to test their vaccines. No other company in the world has
such a portfolio, with only two competitors globally having 1
challenge study model each. hVIVO also works with companies in the
UK and Ireland to provide COVID-19 testing to staff to protect
staff and customers from a workplace COVID-19 outbreak through its
COVID Clear offering.
Open Orphan comprises of two commercial specialist CRO services
businesses, hVIVO and Venn Life Sciences and is also building out a
valuable data platform business. hVIVO has built up one of the
world's largest databases of infectious disease progression data
and we are populating our Open Orphan Health Data platform with
this historical hVIVO data. In our clinical trials going forward,
we are also planning to collect data on volunteer's via wearables
during clinical trials. Therefore, Open Orphan's data, which may
yield valuable digital biomarkers, could be one of the more
sought-after datasets by many of the large wearables /smart watch
wearables providers around the world. In June 2019, Open Orphan
acquired AIM-listed Venn Life Sciences Holdings plc in a reverse
take-over and in January 2020 it completed the merger with hVIVO
plc in January 2020. Venn is an integrated drug development
consultancy firm which offers CMC (chemistry, manufacturing and
controls), preclinical, Phase I & II clinical trials design and
execution. The merger with hVIVO created a European full pharma
services company broadening the Company's customer base and with
complementary specialist CRO services, widened the range of the
Company's service offerings.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAUOUKRRKUAUAA
(END) Dow Jones Newswires
November 24, 2020 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024